News | Heart Valve Technology | May 03, 2017

Baylor Jack and Jane Hamilton Heart and Vascular Hospital Implants CoreValve Evolut Pro Valve

Team is first in United States for specific valve-in-valve case

Baylor Jack and Jane Hamilton Heart and Vascular Hospital Implants CoreValve Evolut Pro Valve

May 3, 2017 — The Baylor Jack and Jane Hamilton Heart and Vascular Hospital (BHVH) transcatheter aortic valve replacement (TAVR) team recently placed the first commercially approved CoreValve Evolut Pro system in Texas. This is also the first Evolut Pro valve placed in a failed bioprosthetic (tissue) aortic valve in the United States.

“The Evolut PRO has a unique ‘skirt’ around the valve that helps minimize leakage; one of the greatest potential risks for TAVR patient outcomes,” said Robert Stoler, M.D., co-medical director of cardiology and medical director, Baylor Heart and Vascular Hospital catheterization lab. “In this procedure, we replaced an old, surgically implanted bioprosthetic aortic valve using a minimally invasive approach, without open-heart surgery.”

During a catheter-based TAVR procedure, an interventional cardiologist or cardiothoracic surgeon makes a small incision in the leg (transfemoral approach), upper chest (direct aortic approach) or shoulder (subclavian approach) to access the vasculature, and then guides the new valve into position to replace the failing aortic valve. Once in place, the device expands and takes over the original valves function to enable blood to flow efficiently out of the heart.

“The addition of the Evolut PRO valve to the program at BHVH continues to bring an advanced generation of research and commercially available valves to aortic stenosis patients in the North Texas region,” Stoler added. “We are pleased to be the first in Texas and one of the first in the U.S. to use this new technology.”

Aortic stenosis is a common problem caused by a narrowing of the heart’s aortic valve due to excessive calcium deposits on the valve leaflets. When the valve narrows, it does not open or close properly, making the heart work harder to pump blood throughout the body. Eventually, this may cause the heart to weaken, potentially leading to heart failure and increased risk for sudden cardiac death.

Interventional cardiologists and cardiothoracic surgeons on the BHVH medical staff have performed TAVR procedures in patients with aortic stenosis for more than five years and recently reached their 500th TAVR.

For more information: www.medtronic.com

Related Content

Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
The ChordArt transcatheter mitral valve leaflet chord replacement system on X-ray, showing the anchoring sections of the artificial chord.

The ChordArt transcatheter mitral valve leaflet chord replacement system on X-ray, showing the anchoring sections of the artificial chord.

News | Heart Valve Technology| August 01, 2017
Aug.
Hitachi and West Virginia University Partner to Advance Left Ventricular Mechanical Function Evaluation
News | Cardiovascular Ultrasound| July 21, 2017
Hitachi Healthcare and the West Virginia University Heart and Vascular Institute announced the formation of a new...
Sponsored Content | Videos | Cardiovascular Surgery| July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Edwards Sapien 3 TAVR valve will be implanted in asymptomatic aortic stenosis patients in the EARLY TAVR Trial
Feature | Heart Valve Technology| July 14, 2017
July 14, 2017 — Morristown Medical Center, part of Atlantic Health System, has randomized the first patient in the wo
Ziosoft's PhyZiodynamics 4-D processing showing a replaced aortic valve

An example of Ziosoft's PhyZiodynamics 4-D processing showing a replaced aortic valve.

Technology | Computed Tomography (CT)| July 12, 2017
July 12, 2017 — At the 2017 annual meeting for the Society of Cardiovascular Computed Tomography (SCCT), Ziosoft show
Medtronic's CoreValve Evolut R gained FDA approval for intermediate risk patients

An illustration of the self-expanding CoreValve Evolut R TAVR valve half deployed in the aortic root.

Feature | Heart Valve Technology| July 10, 2017
The U.S. Food and Drug Administration (FDA) has cleared an additional indication to expand the use Medtronic's self-...
HAART 300 Aortic Annuloplasty Device Sees U.S. Pilot Launch, First Commercial Use
News | Annuloplasty Rings| July 05, 2017
July 5, 2017 — BioStable Science & Engineering Inc.
Overlay Init